RxDoctor Payments Data

Chad Tiede

Optometrist · Chambersburg, PANPI 1730284050

Payments from drug & device makers

$4,657in general payments, 2019–2025

Across 182 payments — averaging $25.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$2K
  • AbbVie$1K
  • Biotissue Holdings Inc.$228
  • Sight Sciences, Inc.$218
  • Alcon$205
  • Bausch & Lomb Americas Inc.$172
  • plus $901 from 14 others

What the payments were for

  • Food & beverage$4,657100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,657 in reported general payments places this provider in the 90th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$294,925
Medicare patients
1,605
Services billed
3,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost122$76,991
RestasisCyclosporine24$34,228
CombiganBrimonidine Tartrate/Timolol33$13,592
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol36$12,336
SimbrinzaBrinzolamide/Brimonidine Tart36$8,715
MieboPerfluorohexyloctane/Pf11$8,222
Cyclosporine14$7,762
CequaCyclosporine12$7,752
Latanoprost385$5,457
Brimonidine Tartrate69$4,475
Prednisolone Acetate47$1,665
Doxycycline Hyclate46$1,495
Timolol Maleate97$1,489
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat66$1,346
ErythromycinErythromycin Base100$816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$1,371$124,811179 claims
AlconSimbrinza$205$8,71536 claims
Bausch & Lomb Americas Inc.Miebo$172$8,22211 claims
Sun Pharmaceutical Industries Inc.Cequa$1,563$7,75212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Chambersburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →